Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 147


ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype.

Smith AM, Findlay VJ, Bandurraga SG, Kistner-Griffin E, Spruill LS, Liu A, Golshayan AR, Turner DP.

Carcinogenesis. 2012 Mar;33(3):572-80. doi: 10.1093/carcin/bgs007. Epub 2012 Jan 9.


ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression.

Kato T, Fujita Y, Nakane K, Kojima T, Nozawa Y, Deguchi T, Ito M.

Biochem Biophys Res Commun. 2012 Jan 20;417(3):966-71. doi: 10.1016/j.bbrc.2011.12.047. Epub 2011 Dec 20.


Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.

Gu L, Liao Z, Hoang DT, Dagvadorj A, Gupta S, Blackmon S, Ellsworth E, Talati P, Leiby B, Zinda M, Lallas CD, Trabulsi EJ, McCue P, Gomella L, Huszar D, Nevalainen MT.

Clin Cancer Res. 2013 Oct 15;19(20):5658-74. doi: 10.1158/1078-0432.CCR-13-0422. Epub 2013 Aug 13.


Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy.

Sharifi N, Kawasaki BT, Hurt EM, Farrar WL.

Cancer Biol Ther. 2006 Aug;5(8):901-6. Epub 2006 Aug 28. Review.


Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.

Thomas C, Zoubeidi A, Kuruma H, Fazli L, Lamoureux F, Beraldi E, Monia BP, MacLeod AR, Thüroff JW, Gleave ME.

Mol Cancer Ther. 2011 Feb;10(2):347-59. doi: 10.1158/1535-7163.MCT-10-0850. Epub 2011 Jan 7.


N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.

Jennbacken K, Tesan T, Wang W, Gustavsson H, Damber JE, Welén K.

Endocr Relat Cancer. 2010 May 18;17(2):469-79. doi: 10.1677/ERC-10-0015. Print 2010 Jun.


Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC.

Cancer Res. 2008 Aug 1;68(15):6407-15. doi: 10.1158/0008-5472.CAN-07-5997.


Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.

Shiota M, Yokomizo A, Naito S.

Free Radic Biol Med. 2011 Oct 1;51(7):1320-8. doi: 10.1016/j.freeradbiomed.2011.07.011. Epub 2011 Jul 23. Review.


Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.

Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, Neumann RD, Nelson CC, Guns ES, Wasan KM.

Prostate. 2010 Mar 1;70(4):390-400. doi: 10.1002/pros.21072.


The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.

Huang KC, Alshalalfa M, Hegazy SA, Dolph M, Donnelly B, Bismar TA.

Cancer Biol Ther. 2014 Sep;15(9):1120-8. doi: 10.4161/cbt.29689. Epub 2014 Jun 27.


Overexpression of ETS-1 is associated with malignant biological features of prostate cancer.

Li B, Shimizu Y, Kobayashi T, Terada N, Yoshimura K, Kamba T, Mikami Y, Inoue T, Nishiyama H, Ogawa O.

Asian J Androl. 2012 Nov;14(6):860-3. doi: 10.1038/aja.2012.107. Epub 2012 Oct 15.


Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.

McGrath MJ, Binge LC, Sriratana A, Wang H, Robinson PA, Pook D, Fedele CG, Brown S, Dyson JM, Cottle DL, Cowling BS, Niranjan B, Risbridger GP, Mitchell CA.

Cancer Res. 2013 Aug 15;73(16):5066-79. doi: 10.1158/0008-5472.CAN-12-4520. Epub 2013 Jun 25.


AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.

McGregor N, Patel L, Craig M, Weidner S, Wang S, Pienta KJ.

J Cell Biochem. 2010 Aug 1;110(5):1187-94. doi: 10.1002/jcb.22633.


Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence.

Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, Nelson CC.

Cancer Res. 2004 Mar 15;64(6):2212-21.


Zyflamend reduces the expression of androgen receptor in a model of castrate-resistant prostate cancer.

Huang EC, Chen G, Baek SJ, McEntee MF, Collier JJ, Minkin S, Biggerstaff J, Whelan J.

Nutr Cancer. 2011 Nov;63(8):1287-96. doi: 10.1080/01635581.2011.606956. Epub 2011 Sep 29.


Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.

Kim J, Roh M, Abdulkadir SA.

BMC Cancer. 2010 Jun 1;10:248. doi: 10.1186/1471-2407-10-248.


Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.

Chen M, Feuerstein MA, Levina E, Baghel PS, Carkner RD, Tanner MJ, Shtutman M, Vacherot F, Terry S, de la Taille A, Buttyan R.

Mol Cancer. 2010 Apr 26;9:89. doi: 10.1186/1476-4598-9-89.


Development of a castrate resistant transplant tumor model of prostate cancer.

Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Pili R.

Prostate. 2012 May 1;72(6):587-91. doi: 10.1002/pros.21465. Epub 2011 Jul 27.


Differential expression of ETS family members in prostate cancer tissues and androgen-sensitive and insensitive prostate cancer cell lines.

Shaikhibrahim Z, Lindstrot A, Langer B, Buettner R, Wernert N.

Int J Mol Med. 2011 Jul;28(1):89-93. doi: 10.3892/ijmm.2011.672. Epub 2011 Apr 13.


Ets-1 is implicated in the regulation of androgen co-regulator FHL2 and reveals specificity for migration, but not invasion, of PC3 prostate cancer cells.

Shaikhibrahim Z, Langer B, Lindstrot A, Florin A, Bosserhoff A, Buettner R, Wernert N.

Oncol Rep. 2011 Apr;25(4):1125-9. doi: 10.3892/or.2011.1156. Epub 2011 Jan 21.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk